ENVISION: Enhanced Neuronal Viability through Interference with Senescence to Improve the Outcome of Neurodegenerative disorders
What about a new approach for neurodegeneration by targeting negative cells surrounding key neurons? Let’s ENVISION!
Envision hypothesizes that scarred cells in the environment can promote neurodegeneration and that targeting these cells may counteract this. This brings together expertise from the UMC Utrecht on the biology of scarred cells (Department of CMM – Center for Molecular Medicine), neurodegeneration (collaborators at Division Brain) and Cleara Biotech B.V. (industry experience with translating anti-scarring compounds).
Neurodegeneration is amongst the most severe types of age-related diseases. The WHO estimates that >55 million people worldwide are living with dementia, with ~10 million new cases per year. Alzhemier’s Disease (AD) contributes for 60-70% to all dementias. Targeting AD has been dubbed the graveyard of drug discovery, with >90% of all trials having failed to deliver. At least in part, this is because much energy has gone into targeting plaques and tangles caused by Aβ and Tau. Alternative solutions are therefore urgently needed.
Whereas the role of the microenvironment is principally acknowledged, much less is clear on how signals thereof might contribute to disease development. WE already obtained preliminary data that scarred cells can impair neuronal biology in vitro and compounds targeting these cells can extend cognitive function in naturally aging mice. Here, we aim to explore whether and how scarred cells may impair neuronal function in advanced 3D neuronal cultures and mice and whether their elimination may also expand cognitive function in models for neurodegeneration, with a focus on AD.
When successful, ENVISIOn will deliver conceptual datasets on which molecular pathways and targetable nodes may promote neurodegeneration (I), proof-of-concept evidence whether targeting these may lead to extende neuronal health and cognitive function (II) and provide a translatable path forward in drug development for compounds that can translate into future clinical trials (III).
Andere projecten
In elk PPS-project werken kennisinstellingen, bedrijven en zorgpartijen samen aan een concrete gezondheidsvraag. Bekijk het volledige projectoverzicht.
Bekijk de programma’s
Binnen onze programma’s werken bedrijven, kennisinstellingen en regionale partners samen aan innovaties die bijdragen aan betere gezondheid en zorg.
Bekijk de partnerschappen
Strategische publiek-private partnerschappen (PPP's) zijn meerjarige samenwerkingen tussen bedrijven, kennisinstellingen en andere partijen.
Hoe kunnen we je helpen?
Heb je een vraag of wil je meer weten over Health Holland? We brengen je graag in contact met de juiste mensen, kennis en mogelijkheden om gezondheidsinnovatie te versnellen.
We hebben uw bericht ontvangen
We nemen binnen 3 tot 4 werkdagen contact met je op. Is je vraag dringend? Neem dan gerust direct contact met ons op. Hieronder zie je de contactoptie die het beste past bij je onderwerp.
Opnieuw beginnen
Er ging iets mis bij het versturen van het formulier. Probeer het opnieuw.